Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer

Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA
Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer ( Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA )
15 Apr 2019

Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model

Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model ( Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas )
15 Apr 2019

Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas

Prof Shoba Navai - Baylor College of Medicine, Houston, USA
Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas ( Prof Shoba Navai - Baylor College of Medicine, Houston, USA )
15 Apr 2019

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI

Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI ( Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA )
15 Apr 2019

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies

Dr James Gulley - National Cancer Institute, Bethesda, USA
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies ( Dr James Gulley - National Cancer Institute, Bethesda, USA )
15 Apr 2019

Using T cell engineering plus triple checkpoint blockade to enhance the efficacy of adoptive immunotherapy in ovarian cancer

Dr Kristin Anderson - Fred Hutchinson Cancer Research Center, Seattle, USA
Using T cell engineering plus triple checkpoint blockade to enhance the efficacy of adoptive immunotherapy in ovarian cancer ( Dr Kristin Anderson - Fred Hutchinson Cancer Research Center, Seattle, USA )
15 Apr 2019

The hereditary link between African-Americans and people in Africa and its relationship to cancer incidence and outcomes

Prof John Carpten - Keck School of Medicine, Los Angeles, USA
The hereditary link between African-Americans and people in Africa and its relationship to cancer incidence and outcomes ( Prof John Carpten - Keck School of Medicine, Los Angeles, USA )
15 Apr 2019

Combining the SLP vaccine with chemo-immunotherapy in order to increase the HPV-specific T-cell response in cervical cancer

Prof Kees Melief - Leiden University Medical Center, Leiden, Netherlands
Combining the SLP vaccine with chemo-immunotherapy in order to increase the HPV-specific T-cell response in cervical cancer ( Prof Kees Melief - Leiden University Medical Center, Leiden, Netherlands )
15 Apr 2019

Digitising clinical assessment and using it for evidence-based prediction of outcomes

Prof Jorge Nieva - Keck School of Medicine, Los Angeles, USA
Digitising clinical assessment and using it for evidence-based prediction of outcomes ( Prof Jorge Nieva - Keck School of Medicine, Los Angeles, USA )
15 Apr 2019

African Access Initiative: Improving patient outcomes in Africa

Jennifer Dent - BIO Ventures for Global Health, Seattle, USA
African Access Initiative: Improving patient outcomes in Africa ( Jennifer Dent - BIO Ventures for Global Health, Seattle, USA )
15 Apr 2019

Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma

Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA
Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma ( Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA )
15 Apr 2019

Risk factors for prostate cancer in men of African descent

Dr Faruk Mohammed - Ahmadu Bello University, Zaria, Nigeria
Risk factors for prostate cancer in men of African descent ( Dr Faruk Mohammed - Ahmadu Bello University, Zaria, Nigeria )
15 Apr 2019